Haleon is recording stronger U.S. sales of products aimed at easing side effects from GLP-1 medications, a class of drugs that mimics a hormone to promote fullness and weight loss. Its products, including Advil, TUMS and Biotène, are being placed both in regular aisles and dedicated sections for GLP-1 users at CVS Pharmacy. The dual-placement strategy produced an average 24% sales lift per store in the first quarter of the year. Haleon said it holds most of the GLP-1 shelf space at CVS, while products on dedicated shelves are outperforming those in stores without such sections. About 11% of Americans are taking GLP-1 weight-loss drugs, according to Gallup. Haleon has also discussed the strategy with Walmart and Target, but did not disclose the outcome of those talks.